This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The advent of new effective therapies for relapsing-remitting (RR) multiple sclerosis (MS) has increased the expectations for disease control. This has made it crucial to use measures able to accurately evaluate the impact of therapeutic intervention, shifting the treatment paradigm of MS from partial response to remission.1
Footnotes
Author contributions: Nicola De Stefano: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval. Maria Laura Stromillo: analysis or interpretation of data, accepts responsibility for conduct of research and final approval, acquisition of data. Antonio Giorgio: drafting/revising the manuscript, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, acquisition of data. Marco Battaglini: analysis or interpretation of data, accepts responsibility for conduct of research and final approval. Maria Letizia Bartolozzi: study concept or design, accepts responsibility for conduct of research and final approval, acquisition of data. Maria Pia Amato: drafting/revising the manuscript, study concept or design, accepts responsibility for conduct of research and final approval, acquisition of data. Maria Pia Sormani: drafting/revising the manuscript, study concept or design, analysis or interpretation of data, accepts responsibility for conduct of research and final approval, statistical analysis.
Study funding: Supported by a grant from FISM (Fondazione Italiana Sclerosi Multipla) Cod. 2010/R/15.
Disclosure: N. De Stefano has received honoraria from Schering, Biogen-Idec, Teva, Novartis, Genzyme, and Merck Serono S.A. for consulting services, speaking, and travel support. He serves on advisory boards for Merck Serono S.A. and Novartis. He has received research grant support from the Italian MS Society. M. Stromillo, A. Giorgio, M. Battaglini, and M. Bartolozzi report no disclosures relevant to the manuscript. M. Amato serves on scientific advisory boards for Biogen Idec, Merck Serono, Bayer Schering, Teva, and Sanofi Aventis and receives research support and honoraria for speaking from Biogen Idec, Merck Serono, Bayer Schering, Teva, Novartis, and Sanofi Aventis. M. Sormani has received personal compensation for consulting services and for speaking activities from Genzyme, Merck Serono, Teva, Synthon, Actelion, Novartis, and Biogen Idec. Go to Neurology.org for full disclosures.
- Received March 4, 2015.
- Accepted in final form July 13, 2015.
- © 2015 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.